CytoDyn Appoints Maura Fleming as Vice President,
Post# of 154001
(Total Views: 579)
Posted On: 01/23/2020 8:05:44 AM
CytoDyn Appoints Maura Fleming as Vice President, General Counsel and Corporate Secretary
Download as PDFJanuary 23, 2020 8:00am EST
VANCOUVER, Washington, Jan. 23, 2020 (GLOBE NEWSWIRE) --
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Maura Fleming as the Company’s vice president, general counsel and corporate secretary. Ms. Fleming joins CytoDyn with extensive experience in transactional, corporate and commercial law, in addition to experience in governance, securities and compliance.
“We are excited to welcome Maura to the CytoDyn team,” said Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn. “Her entrepreneurial spirit, broad legal background and experience in navigating the corporate life cycle strengthens our leadership team at this pivotal time. Maura will assist the CytoDyn team execute its goals as the Company continues to advance its targeted therapy, leronlimab, to address cancer, HIV and other autoimmune diseases.”
Ms. Fleming added, “I am honored to join CytoDyn and look forward to leveraging my strategic and legal insight to advise the Company during this unprecedented period of extensive growth and evolution. I am eager to start working alongside the leadership team and support the continuing evolution of its corporate governance, transactions and other legal challenges.”
Ms. Fleming has over 10 years of experience working in corporate transactional law. Before joining CytoDyn, Ms. Fleming served as counsel for Holland & Hart LLP, where she was responsible for providing legal expertise and contract management services across technology, natural foods and beverages, manufacturing, natural resources and various other industries. Prior to Holland & Hart LLP, Ms. Fleming served as senior corporate counsel at Shutterfly, a publicly traded company specialized in personal products and services, where she oversaw all aspects of the corporate life cycle and provided strategic insight on corporate risk while ensuring compliance with essential legal requirements. Ms. Fleming also served as director of legal services at Aerohive Networks, Inc., where she was involved in all aspects of the software company’s legal processes. Additionally, Ms. Fleming worked as an associate at Wilson Sonsini Goodrich & Rosati, representing and advising private companies as well as supporting public companies at every stage of the corporate life cycle. Ms. Fleming began her career at Yahoo! Inc., where she worked for seven years and held increasing roles of responsibility ultimately leading to her role as senior compliance paralegal. She received her J.D. from Santa Clara University School of Law and her bachelor of arts degree in international relations from the University of California, Davis.
Download as PDFJanuary 23, 2020 8:00am EST
VANCOUVER, Washington, Jan. 23, 2020 (GLOBE NEWSWIRE) --
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Maura Fleming as the Company’s vice president, general counsel and corporate secretary. Ms. Fleming joins CytoDyn with extensive experience in transactional, corporate and commercial law, in addition to experience in governance, securities and compliance. “We are excited to welcome Maura to the CytoDyn team,” said Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn. “Her entrepreneurial spirit, broad legal background and experience in navigating the corporate life cycle strengthens our leadership team at this pivotal time. Maura will assist the CytoDyn team execute its goals as the Company continues to advance its targeted therapy, leronlimab, to address cancer, HIV and other autoimmune diseases.”
Ms. Fleming added, “I am honored to join CytoDyn and look forward to leveraging my strategic and legal insight to advise the Company during this unprecedented period of extensive growth and evolution. I am eager to start working alongside the leadership team and support the continuing evolution of its corporate governance, transactions and other legal challenges.”
Ms. Fleming has over 10 years of experience working in corporate transactional law. Before joining CytoDyn, Ms. Fleming served as counsel for Holland & Hart LLP, where she was responsible for providing legal expertise and contract management services across technology, natural foods and beverages, manufacturing, natural resources and various other industries. Prior to Holland & Hart LLP, Ms. Fleming served as senior corporate counsel at Shutterfly, a publicly traded company specialized in personal products and services, where she oversaw all aspects of the corporate life cycle and provided strategic insight on corporate risk while ensuring compliance with essential legal requirements. Ms. Fleming also served as director of legal services at Aerohive Networks, Inc., where she was involved in all aspects of the software company’s legal processes. Additionally, Ms. Fleming worked as an associate at Wilson Sonsini Goodrich & Rosati, representing and advising private companies as well as supporting public companies at every stage of the corporate life cycle. Ms. Fleming began her career at Yahoo! Inc., where she worked for seven years and held increasing roles of responsibility ultimately leading to her role as senior compliance paralegal. She received her J.D. from Santa Clara University School of Law and her bachelor of arts degree in international relations from the University of California, Davis.
(2)
(0)